Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Governance Documents Committees Year None20232022 March 22, 2023 Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders March 14, 2023 Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting February 21, 2023 Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy January 6, 2023 Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference ◄ ◄ Page 1 Current page 2 Displaying 11 - 14 of 14 BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Data Provided by Refinitiv. Minimum 15 minutes delayed.
Year None20232022 March 22, 2023 Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders March 14, 2023 Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting February 21, 2023 Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy January 6, 2023 Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference ◄ ◄ Page 1 Current page 2 Displaying 11 - 14 of 14
March 22, 2023 Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
March 14, 2023 Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
February 21, 2023 Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
